Is a dosing schedule of 200 mg iron sucrose in 100 mL over 15 minutes three times weekly appropriate for a patient with a ferritin level of 5 ng/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Iron Sucrose 200 mg Three Times Weekly is Acceptable for Severe Iron Deficiency

For a patient with critically low ferritin of 5 ng/mL, administering 200 mg iron sucrose in 100 mL over 15 minutes three times weekly is both appropriate and supported by FDA labeling and clinical guidelines.

Dosing Rationale

The proposed regimen aligns with FDA-approved dosing for iron sucrose (Venofer). The FDA label explicitly supports 200 mg doses administered during sequential sessions, with clinical trials demonstrating safety and efficacy using this exact dosing schedule 1. Multiple studies have successfully used 200 mg weekly or more frequently without safety concerns 2, 3, 4.

Key Supporting Evidence:

  • FDA-approved dosing: Iron sucrose can be administered as 200 mg doses during sequential dialysis sessions, with studies showing 200 mg given 5 times within 14 days 1
  • Infusion duration: The 15-minute infusion time is acceptable. FDA labeling indicates 200 mg can be given over 2-5 minutes as IV push 1, making a 15-minute infusion conservative and safe 1
  • Frequency: Three times weekly dosing is well-established, particularly in hemodialysis populations where this schedule is standard 1, 4

Clinical Context for Ferritin of 5 ng/mL

A ferritin level of 5 ng/mL represents severe iron deficiency requiring aggressive repletion. This patient needs rapid iron restoration, which oral iron cannot achieve effectively.

Why IV Iron is Preferred:

According to current guidelines, IV iron should be used when:

  • Oral iron is ineffective or poorly tolerated 5
  • Rapid iron repletion is needed 5, 6
  • Iron stores are severely depleted (ferritin <15-30 ng/mL) 6

Formulations requiring 1-2 infusions are generally preferred 5, but iron sucrose remains a valid option when:

  • Other formulations are unavailable or contraindicated
  • Cost is a significant consideration (iron sucrose costs $441.50 per 1000 mg vs $3470-3896 for single-dose alternatives) 5
  • The patient can accommodate multiple visits

Safety Considerations

Infusion Reactions:

  • Hypersensitivity reactions occur in approximately 0.5% of patients 6
  • For mild reactions: stop infusion, restart after 15 minutes at slower rate 5
  • Avoid diphenhydramine premedication as side effects can mimic worsening reactions 5

Monitoring Requirements:

  • During infusion: Observe for complement activation-related pseudo-allergy (not true allergy) 5
  • Post-treatment: Check hemoglobin and ferritin after completing induction course
  • Long-term: Monitor CBC every 3 months for 12 months, then every 6 months for 2-3 years 6

Important Caveats:

Hypophosphatemia risk is minimal with iron sucrose compared to ferric carboxymaltose. Recent data shows iron sucrose causes significantly less hypophosphatemia than FCM 7. This is particularly relevant if repeated dosing is anticipated.

Expected Outcomes

Based on clinical trial data with this regimen:

  • Hemoglobin increase: Expect 1.1-1.7 g/dL rise within 4 weeks 1
  • Ferritin increase: Mean increase of 266-435 ng/mL from baseline 1
  • Transferrin saturation: Improvement of 8-14% 1
  • Response rate: 94-95% of patients achieve therapeutic goals 3, 4

Alternative Consideration

While the proposed regimen is acceptable, consider single-dose alternatives if logistically feasible:

  • Ferric carboxymaltose: 750-1000 mg in 1-2 doses 5
  • Low-molecular-weight iron dextran: 1000 mg single dose 5
  • Ferric derisomaltose: 1000 mg single dose 5

These reduce infusion visits from 5-10 down to 1-2, improving convenience without compromising safety or efficacy 5, 6. However, they cost 8-10 times more than iron sucrose 5.

The bottom line: Your proposed iron sucrose regimen is FDA-approved, guideline-supported, and clinically appropriate for this patient's severe iron deficiency 1, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.